And GSK’s first-to-market Arexvy lived up to that expectation with $1.5 billion sales in its first year of commercialization. Related As RSV vaccine clash kicks off, GSK sues Pfizer for patent ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best ADR stocks. American Depositary Receipts (ADR) are US-listed securities that represent shares ...

GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I’d seen in the stock before that. When investing, your capital is at risk ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other most undervalued biotech stocks to invest in. On February 21, Jared Holz, Mizuho Securities ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its plans to create a six-month regimen are shaping up. ViiV, which is ...

Elizabeth Warren (D-Mass.) is asking a federal watchdog to investigate GSK for replacing a popular asthma inhaler with a so-called authorized generic at a much higher price in order to avoid ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former GSK leaders to its board. The biotech’s series B was led by new ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...